Details of the Drug

General Information of Drug (ID: DMIF7KG)

Drug Name
PMID27977313-Compound-29
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 217.31
Topological Polar Surface Area (xlogp) 2.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C14H19NO
IUPAC Name
2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one
Canonical SMILES
CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C
InChI
InChI=1S/C14H19NO/c1-10-6-7-13(11(2)8-10)14(16)12(3)9-15(4)5/h6-8H,3,9H2,1-2,4-5H3
InChIKey
QXLQZLBNPTZMRK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
436058
CAS Number
116218-49-6
TTD ID
D0PT8T
ACDINA ID
D01322

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytoplasmic thioredoxin reductase (TXNRD1) TTR7UJ3 TRXR1_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as PMID27977313-Compound-29
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
PMID28454500-Compound-96 DM2A75P Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and PMID28454500-Compound-96. Discovery agent [N.A.] [3]
Coadministration of a Drug Treating the Disease Different from PMID27977313-Compound-29 (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [4]
Tretinoin DM49DUI Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tretinoin. Acne vulgaris [ED80] [3]
Isotretinoin DM4QTBN Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Isotretinoin. Acne vulgaris [ED80] [3]
Nicotinamide DMUPE07 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [5]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Thioguanine. Acute myeloid leukaemia [2A60] [6]
Chlorzoxazone DMCYVDT Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Chlorzoxazone. Acute pain [MG31] [3]
Oxandrolone DMU9MYJ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Oxandrolone. Alcoholic liver disease [DB94] [3]
Tacrine DM51FY6 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tacrine. Alzheimer disease [8A20] [3]
Dronedarone DMA8FS5 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Dronedarone. Angina pectoris [BA40] [3]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [7]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Oxymetholone. Aplastic anaemia [3A70] [3]
Voriconazole DMAOL2S Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Voriconazole. Aspergillosis [1F20] [3]
Posaconazole DMUL5EW Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Posaconazole. Aspergillosis [1F20] [3]
Zafirlukast DMHNQOG Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Zafirlukast. Asthma [CA23] [3]
Zileuton DMVRIC2 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Zileuton. Asthma [CA23] [3]
Atomoxetine DM5L6HI Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [3]
Clavulanate DM2FGRT Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Clavulanate. Bacterial infection [1A00-1C4Z] [5]
Trovafloxacin DM6AN32 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trovafloxacin. Bacterial infection [1A00-1C4Z] [3]
Sulfamethoxazole DMB08GE Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [3]
Oxytetracycline DMOVH1M Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Oxytetracycline. Bacterial infection [1A00-1C4Z] [3]
Levofloxacin DMS60RB Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Levofloxacin. Bacterial infection [1A00-1C4Z] [3]
Moxifloxacin DMU8V4S Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Moxifloxacin. Bacterial infection [1A00-1C4Z] [3]
Minocycline DMVN5OH Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Minocycline. Bacterial infection [1A00-1C4Z] [3]
Telithromycin DMZ4P3A Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Telithromycin. Bacterial infection [1A00-1C4Z] [3]
Tetracycline DMZA017 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tetracycline. Bacterial infection [1A00-1C4Z] [3]
Temozolomide DMKECZD Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Temozolomide. Brain cancer [2A00] [3]
Lomustine DMMWSUL Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lomustine. Brain cancer [2A00] [3]
Lapatinib DM3BH1Y Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lapatinib. Breast cancer [2C60-2C6Y] [3]
Pralatrexate DMAO80I Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pralatrexate. Breast cancer [2C60-2C6Y] [3]
Tucatinib DMBESUA Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tucatinib. Breast cancer [2C60-2C6Y] [3]
Tamoxifen DMLB0EZ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tamoxifen. Breast cancer [2C60-2C6Y] [3]
Bosutinib DMTI8YE Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bosutinib. Breast cancer [2C60-2C6Y] [3]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [5]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fluoxymesterone. Breast cancer [2C60-2C6Y] [3]
Demeclocycline DMZEPFJ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Demeclocycline. Bronchitis [CA20] [3]
Atorvastatin DMF28YC Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [3]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [3]
Macitentan DMP79A1 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Macitentan. Cardiovascular disease [BA00-BE2Z] [3]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Chenodiol. Cholelithiasis [DC11] [3]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Phenylbutazone. Chronic pain [MG30] [8]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ketoprofen. Chronic pain [MG30] [8]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Anisindione. Coagulation defect [3B10] [8]
Regorafenib DMHSY1I Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Regorafenib. Colorectal cancer [2B91] [3]
Oxaliplatin DMQNWRD Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Oxaliplatin. Colorectal cancer [2B91] [3]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Intedanib. Colorectal cancer [2B91] [3]
Drospirenone DM1A9W3 Moderate Decreased metabolism of PMID27977313-Compound-29 caused by Drospirenone mediated hepatotoxicity. Contraceptive management [QA21] [4]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of PMID27977313-Compound-29 caused by Levonorgestrel mediated hepatotoxicity. Contraceptive management [QA21] [4]
Desogestrel DM27U4Y Moderate Decreased metabolism of PMID27977313-Compound-29 caused by Desogestrel mediated hepatotoxicity. Contraceptive management [QA21] [4]
Norgestimate DMYP4XC Moderate Decreased metabolism of PMID27977313-Compound-29 caused by Norgestimate mediated hepatotoxicity. Contraceptive management [QA21] [4]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ardeparin. Coronary thrombosis [BA43] [8]
Pasireotide DMHM7JS Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pasireotide. Cushing syndrome [5A70] [3]
Ivacaftor DMZC1HS Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ivacaftor. Cystic fibrosis [CA25] [3]
Ethanol DMDRQZU Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ethanol. Cystitis [GC00] [3]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Danaparoid. Deep vein thrombosis [BD71] [8]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Rivaroxaban. Deep vein thrombosis [BD71] [8]
Nefazodone DM4ZS8M Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nefazodone. Depression [6A70-6A7Z] [3]
Duloxetine DM9BI7M Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Duloxetine. Depression [6A70-6A7Z] [3]
Milnacipran DMBFE74 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Milnacipran. Depression [6A70-6A7Z] [3]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [3]
Felbamate DM1V5ZS Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Felbamate. Epilepsy/seizure [8A61-8A6Z] [3]
Mephenytoin DM5UGDK Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [3]
Valproate DMCFE9I Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Valproate. Epilepsy/seizure [8A61-8A6Z] [3]
Phenytoin DMNOKBV Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Phenytoin. Epilepsy/seizure [8A61-8A6Z] [3]
Fosphenytoin DMOX3LB Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [3]
Carbamazepine DMZOLBI Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [3]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Cannabidiol. Epileptic encephalopathy [8A62] [9]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Mefenamic acid. Female pelvic pain [GA34] [8]
Dantrolene DM1D8XY Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Dantrolene. Fever [MG26] [3]
Itraconazole DMCR1MV Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Itraconazole. Fungal infection [1F29-1F2F] [3]
Caspofungin DMGQIPT Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Caspofungin. Fungal infection [1F29-1F2F] [3]
Terbinafine DMI6HUW Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Terbinafine. Fungal infection [1F29-1F2F] [3]
Clotrimazole DMMFCIH Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Clotrimazole. Fungal infection [1F29-1F2F] [3]
Fluconazole DMOWZ6B Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fluconazole. Fungal infection [1F29-1F2F] [3]
Ketoconazole DMPZI3Q Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ketoconazole. Fungal infection [1F29-1F2F] [3]
Atovaquone DMY4UMW Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Atovaquone. Fungal infection [1F29-1F2F] [3]
Sunitinib DMCBJSR Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sunitinib. Gastrointestinal stromal tumour [2B5B] [3]
Ramipril DM2R68E Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ramipril. Heart failure [BD10-BD1Z] [3]
Interferon alfacon-1 DM90WJH Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Interferon alfacon-1. Hepatitis virus infection [1E50-1E51] [3]
Lamivudine DMI347A Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lamivudine. Hepatitis virus infection [1E50-1E51] [3]
Isoniazid DM5JVS3 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [3]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Brentuximab vedotin. Hodgkin lymphoma [2B30] [10]
Zidovudine DM4KI7O Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Zidovudine. Human immunodeficiency virus disease [1C60-1C62] [3]
Stavudine DM6DEK9 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Stavudine. Human immunodeficiency virus disease [1C60-1C62] [3]
Nevirapine DM6HX9B Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nevirapine. Human immunodeficiency virus disease [1C60-1C62] [3]
Tipranavir DM8HJX6 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [3]
Emtricitabine DMBMUWZ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Emtricitabine. Human immunodeficiency virus disease [1C60-1C62] [3]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [11]
Rilpivirine DMJ0QOW Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [3]
Abacavir DMMN36E Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Abacavir. Human immunodeficiency virus disease [1C60-1C62] [3]
Darunavir DMN3GCH Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Darunavir. Human immunodeficiency virus disease [1C60-1C62] [3]
Maraviroc DMTL94F Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [3]
Ritonavir DMU764S Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ritonavir. Human immunodeficiency virus disease [1C60-1C62] [3]
Simvastatin DM30SGU Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Simvastatin. Hyper-lipoproteinaemia [5C80] [3]
Fluvastatin DM4MDJY Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fluvastatin. Hyper-lipoproteinaemia [5C80] [3]
Pravastatin DM6A0X7 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pravastatin. Hyper-lipoproteinaemia [5C80] [3]
Lovastatin DM9OZWQ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lovastatin. Hyper-lipoproteinaemia [5C80] [3]
Fenofibrate DMFKXDY Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fenofibrate. Hyper-lipoproteinaemia [5C80] [3]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Mipomersen. Hyper-lipoproteinaemia [5C80] [12]
Rosuvastatin DMMIQ7G Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [3]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Teriflunomide. Hyper-lipoproteinaemia [5C80] [13]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and BMS-201038. Hyper-lipoproteinaemia [5C80] [14]
Cerivastatin DMXCM7H Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Cerivastatin. Hyper-lipoproteinaemia [5C80] [3]
Moexipril DM26E4B Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Moexipril. Hypertension [BA00-BA04] [3]
Captopril DM458UM Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Captopril. Hypertension [BA00-BA04] [3]
Trandolapril DM4L6EU Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trandolapril. Hypertension [BA00-BA04] [3]
Methyldopa DM5I621 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Methyldopa. Hypertension [BA00-BA04] [3]
Fosinopril DM9NJ52 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fosinopril. Hypertension [BA00-BA04] [3]
Enalapril DMNFUZR Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Enalapril. Hypertension [BA00-BA04] [3]
Perindopril DMOPZDT Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Perindopril. Hypertension [BA00-BA04] [3]
Quinapril DMR8H31 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Quinapril. Hypertension [BA00-BA04] [3]
Lisinopril DMUOK4C Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lisinopril. Hypertension [BA00-BA04] [3]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Dipyridamole. Hypertension [BA00-BA04] [8]
Tolvaptan DMIWFRL Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [3]
Pirfenidone DM6VZFQ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pirfenidone. Idiopathic interstitial pneumonitis [CB03] [3]
Vitamin B3 DMQVRZH Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Vitamin B3. Inborn lipid metabolism error [5C52] [3]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [3]
Febuxostat DMDEXQ0 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [3]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [8]
Ticlopidine DMO946V Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ticlopidine. Ischaemic/haemorrhagic stroke [8B20] [8]
DTI-015 DMXZRW0 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and DTI-015. Liver cancer [2C12] [3]
Testosterone DM7HUNW Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Testosterone. Low bone mass disorder [FB83] [3]
Crizotinib DM4F29C Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Crizotinib. Lung cancer [2C25] [3]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lurbinectedin. Lung cancer [2C25] [3]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Alectinib. Lung cancer [2C25] [3]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and BIBW 2992. Lung cancer [2C25] [3]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pralsetinib. Lung cancer [2C25] [3]
Capmatinib DMYCXKL Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Capmatinib. Lung cancer [2C25] [3]
Sulphadoxine DMZI2UF Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulphadoxine. Malaria [1F40-1F45] [3]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Idelalisib. Mature B-cell leukaemia [2A82] [15]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Clofarabine. Mature B-cell lymphoma [2A85] [16]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Blinatumomab. Mature B-cell lymphoma [2A85] [3]
Vincristine DMINOX3 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Vincristine. Mature B-cell lymphoma [2A85] [3]
Mercaptopurine DMTM2IK Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Mercaptopurine. Mature B-cell lymphoma [2A85] [3]
Ponatinib DMYGJQO Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ponatinib. Mature B-cell lymphoma [2A85] [3]
Cytarabine DMZD5QR Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Cytarabine. Mature B-cell lymphoma [2A85] [3]
Vemurafenib DM62UG5 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Vemurafenib. Melanoma [2C30] [3]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ipilimumab. Melanoma [2C30] [3]
Interferon alfa-2B DMWCQP4 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Interferon alfa-2B. Melanoma [2C30] [3]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of PMID27977313-Compound-29 caused by Ethinyl estradiol mediated hepatotoxicity. Menopausal disorder [GA30] [4]
Danazol DML8KTN Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Danazol. Menstrual cycle bleeding disorder [GA20] [3]
Exjade DMHPRWG Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Exjade. Mineral absorption/transport disorder [5C64] [3]
Riluzole DMECBWN Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Riluzole. Motor neuron disease [8B60] [3]
Carfilzomib DM48K0X Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Carfilzomib. Multiple myeloma [2A83] [3]
Panobinostat DM58WKG Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Panobinostat. Multiple myeloma [2A83] [3]
Lenalidomide DM6Q7U4 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lenalidomide. Multiple myeloma [2A83] [3]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of PMID27977313-Compound-29 and Thalidomide. Multiple myeloma [2A83] [17]
Bortezomib DMNO38U Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bortezomib. Multiple myeloma [2A83] [3]
Interferon beta-1a DM1A6RV Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Interferon beta-1a. Multiple sclerosis [8A40] [18]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tecfidera. Multiple sclerosis [8A40] [3]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of PMID27977313-Compound-29 and Siponimod. Multiple sclerosis [8A40] [4]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of PMID27977313-Compound-29 and Fingolimod. Multiple sclerosis [8A40] [19]
Interferon beta-1b DMCN61Z Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Interferon beta-1b. Multiple sclerosis [8A40] [18]
Pyrazinamide DM4IF32 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pyrazinamide. Mycobacterium infection [1B10-1B21] [3]
Nilotinib DM7HXWT Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nilotinib. Myeloproliferative neoplasm [2A20] [3]
Imatinib DM7RJXL Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Imatinib. Myeloproliferative neoplasm [2A20] [3]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Prasugrel. Myocardial infarction [BA41-BA43] [8]
Bupropion DM5PCS7 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bupropion. Nicotine use disorder [6C4A] [3]
Entrectinib DMMPTLH Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Entrectinib. Non-small cell lung cancer [2C25] [3]
Orlistat DMRJSP8 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Orlistat. Obesity [5B80-5B81] [3]
Rofecoxib DM3P5DA Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Rofecoxib. Osteoarthritis [FA00-FA05] [3]
Valdecoxib DMAY7H4 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Valdecoxib. Osteoarthritis [FA00-FA05] [3]
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Diclofenac. Osteoarthritis [FA00-FA05] [5]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Naproxen. Osteoarthritis [FA00-FA05] [8]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Aspirin. Pain [MG30-MG3Z] [8]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Etodolac. Pain [MG30-MG3Z] [8]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Diflunisal. Pain [MG30-MG3Z] [8]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ibuprofen. Pain [MG30-MG3Z] [8]
Nabumetone DMAT2XH Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Nabumetone. Pain [MG30-MG3Z] [8]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Piroxicam. Pain [MG30-MG3Z] [8]
Acetaminophen DMUIE76 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Acetaminophen. Pain [MG30-MG3Z] [3]
Tolcapone DM8MNVO Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tolcapone. Parkinsonism [8A00] [3]
Doxycycline DM7ICNU Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Doxycycline. Periodontal disease [DA0C] [3]
Ketorolac DMI4EL5 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ketorolac. Postoperative inflammation [1A00-CA43] [8]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Bromfenac. Postoperative inflammation [1A00-CA43] [8]
ABIRATERONE DM8V75C Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and ABIRATERONE. Prostate cancer [2C82] [3]
Nilutamide DMFN07X Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nilutamide. Prostate cancer [2C82] [3]
Flutamide DMK0O7U Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Flutamide. Prostate cancer [2C82] [3]
Bicalutamide DMZMSPF Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bicalutamide. Prostate cancer [2C82] [3]
Acitretin DM8BKU9 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Acitretin. Psoriasis [EA90] [3]
Infliximab DMH7OIA Major Additive immunosuppressive effects by the combination of PMID27977313-Compound-29 and Infliximab. Psoriasis [EA90] [20]
Bosentan DMIOGBU Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bosentan. Pulmonary hypertension [BB01] [3]
Axitinib DMGVH6N Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Axitinib. Renal cell carcinoma [2C90] [3]
Sorafenib DMS8IFC Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sorafenib. Renal cell carcinoma [2C90] [3]
Sulfadiazine DMTW3R8 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfadiazine. Rheumatic fever [1B40] [3]
Salsalate DM13P4C Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Salsalate. Rheumatoid arthritis [FA20] [8]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Meloxicam. Rheumatoid arthritis [FA20] [8]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Sulindac. Rheumatoid arthritis [FA20] [8]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tocilizumab. Rheumatoid arthritis [FA20] [3]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Oxaprozin. Rheumatoid arthritis [FA20] [8]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Flurbiprofen. Rheumatoid arthritis [FA20] [8]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of PMID27977313-Compound-29 and Golimumab. Rheumatoid arthritis [FA20] [20]
Sulfasalazine DMICA9H Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfasalazine. Rheumatoid arthritis [FA20] [3]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Fenoprofen. Rheumatoid arthritis [FA20] [8]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sarilumab. Rheumatoid arthritis [FA20] [3]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Leflunomide. Rheumatoid arthritis [FA20] [13]
Indomethacin DMSC4A7 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Indomethacin. Rheumatoid arthritis [FA20] [8]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Tolmetin. Rheumatoid arthritis [FA20] [8]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of PMID27977313-Compound-29 when combined with Anthrax vaccine. Sepsis [1G40-1G41] [21]
Gefitinib DM15F0X Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Gefitinib. Solid tumour/cancer [2A00-2F9Z] [3]
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [3]
PDX-101 DM6OC53 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and PDX-101. Solid tumour/cancer [2A00-2F9Z] [3]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [9]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [4]
Norethindrone DMTY169 Moderate Decreased metabolism of PMID27977313-Compound-29 caused by Norethindrone mediated hepatotoxicity. Solid tumour/cancer [2A00-2F9Z] [4]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [3]
Disulfiram DMCL2OK Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Disulfiram. Substance abuse [6C40] [3]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Naltrexone. Substance abuse [6C40] [22]
Zithromax DMN4H2O Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Zithromax. Syphilis [1A61-1A6Z] [3]
Eltrombopag DMOGFIX Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Eltrombopag. Thrombocytopenia [3B64] [3]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Caplacizumab. Thrombocytopenia [3B64] [8]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Apixaban. Thrombosis [DB61-GB90] [8]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Cangrelor. Thrombosis [DB61-GB90] [8]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Brilinta. Thrombosis [DB61-GB90] [8]
Dicumarol DMFQCB1 Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Dicumarol. Thrombosis [DB61-GB90] [8]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Clopidogrel. Thrombosis [DB61-GB90] [8]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lenvatinib. Thyroid cancer [2D10] [3]
Methimazole DM25FL8 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Methimazole. Thyrotoxicosis [5A02] [3]
Propylthiouracil DM6D7N8 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Propylthiouracil. Thyrotoxicosis [5A02] [3]
Trimetrexate DMDEA85 Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trimetrexate. Toxoplasmosis [1F57] [3]
Ethambutol DMR87LC Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ethambutol. Tuberculosis [1B10-1B12] [3]
Nitrofurantoin DM7PQIK Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nitrofurantoin. Urinary tract infection [GC08] [3]
Sulfamethizole DMGCHDS Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfamethizole. Urinary tract infection [GC08] [3]
Sulfisoxazole DMXLT8C Moderate Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfisoxazole. Urinary tract infection [GC08] [3]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Betrixaban. Venous thromboembolism [BD72] [8]
⏷ Show the Full List of 224 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium chloride E00077 5234 Diluent; Tonicity agent
Water E00035 962 Solvent
Trisodium Phosphate E00284 24243 Other agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Pegaspargase 750 units/vial injectable 750 units/vial Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
4 Cerner Multum, Inc. "Australian Product Information.".
5 Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
6 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
7 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
8 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
11 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
12 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
13 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
14 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
15 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
16 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
17 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
18 Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
19 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
20 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
21 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
22 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.